Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MNKD

DatePrice TargetRatingAnalyst
2/10/2025$11.00Outperform
Wedbush
12/20/2024$9.00Overweight
Wells Fargo
12/19/2024$7.00 → $10.00Sector Perform → Outperform
RBC Capital Mkts
9/9/2024$7.00 → $8.00Outperform
Leerink Partners
6/13/2024$8.00Buy
Rodman & Renshaw
10/10/2023$10.00Outperform
Wedbush
2/28/2022$6.50 → $6.00Buy
HC Wainwright & Co.
More analyst ratings

$MNKD
Press Releases

Fastest customizable press release news feed in the world

See more
  • MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    2024 revenues of $286M, +43% v. 2023; 4Q 2024 revenues of $77M, +31% v. 4Q 20232024 net income of $28M; Non-GAAP net income of $68M 4Q 2024 net income of $7M; Non-GAAP net income of $23MReduced debt principal by $236M; remaining convertible debt of $36MYear-end 2024 cash, cash equivalents and investments of $203MAdvanced pipeline: Reported primary endpoint of INHALE-1 for Afrezza in pediatricsProgressed MNKD-101 to Global Phase 3Completed Phase 1 of MNKD-201 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter and year ended December 31, 2024, and provided a business update. "Th

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), will release its 2024 fourth quarter and full year financial results after market close on Wednesday, February 26, 2025. MannKind will host a webcast beginning at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same locatio

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MannKind to Present at Upcoming Investor Conferences

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced its participation at three investor conferences during the first quarter of 2025. MannKind's Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during the following investor conferences: Oppenheimer 35th Annual Healthcare Life Sciences Conference (virtual)Tuesday, February 11, 11:20 a.m. ET Leerink Partners 2025 Global Healthcare Conference

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MNKD
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MNKD
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$MNKD
SEC Filings

See more

$MNKD
Leadership Updates

Live Leadership Updates

See more
  • MannKind Extends Collaboration With Thirona Bio on Fibrotic Lung Diseases

    MannKind purchased an additional convertible note issued by Thirona BioNonclinical PD study of MNKD-501 planned, with results anticipated in 2Q 2022MannKind's CEO appointed as a member of the Thirona board of directors DANBURY, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced that has extended its collaboration with Thirona Bio, Inc. ("Thirona") with the purchase of a second convertible note issued by Thirona, and the appointment of Michael Castagna, PharmD as a member of the Thirona board of directors.

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MNKD
Financials

Live finance-specific insights

See more
  • MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    2024 revenues of $286M, +43% v. 2023; 4Q 2024 revenues of $77M, +31% v. 4Q 20232024 net income of $28M; Non-GAAP net income of $68M 4Q 2024 net income of $7M; Non-GAAP net income of $23MReduced debt principal by $236M; remaining convertible debt of $36MYear-end 2024 cash, cash equivalents and investments of $203MAdvanced pipeline: Reported primary endpoint of INHALE-1 for Afrezza in pediatricsProgressed MNKD-101 to Global Phase 3Completed Phase 1 of MNKD-201 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today reported financial results for the quarter and year ended December 31, 2024, and provided a business update. "Th

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025

    DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), will release its 2024 fourth quarter and full year financial results after market close on Wednesday, February 26, 2025. MannKind will host a webcast beginning at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind's website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same locatio

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

    Company plans to meet with FDA regarding potential sNDA submission in 1H 2025Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced six-month results from its Phase 3 INHALE-1 study of Afrezza (insulin human) Inhalation Powder in children and adolescents (aged 4-17 years of age). MannKind expects to submit a request for a supplemental new drug application (sNDA) meeting with

    $MNKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MNKD
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more